Granules India has announced its audited financial results for the fourth quarter and financial year ended March 31, 2026, demonstrating solid performance across key metrics. The Board of Directors approved the standalone and consolidated results at their meeting held on April 29, 2026, with statutory auditors M/s. S R Batliboi & Associates LLP issuing an unmodified opinion on the financial statements.

Consolidated Financial Performance

The company's consolidated financial results for FY26 showed significant improvement in profitability. Net profit for the year increased 18.7% to ₹5,950.21 million from ₹5,015.16 million in the previous year. For Q4 FY26, net profit stood at ₹2,015.68 million compared to ₹1,520.31 million in the corresponding quarter of the previous year.

Total revenue from operations for FY26 reached ₹53,656.42 million, representing a 19.8% growth from ₹44,816.08 million in FY25. Q4 FY26 revenue stood at ₹14,706.08 million compared to ₹11,974.29 million in Q4 FY25.

Operational Efficiency and Margins

The company's operational metrics demonstrated improvement during the year. EBITDA for Q4 surged 39.7% year-over-year to ₹3,520 million from ₹2,520 million, indicating enhanced operational efficiency. The EBITDA margin expansion to 24.16% from 21.07% represents an improvement of over 300 basis points, reflecting the company's focus on operational excellence.

Key Developments and Strategic Initiatives

During FY26, Granules India completed significant strategic acquisitions. Senn Chemicals AG became a wholly owned step-down subsidiary effective April 10, 2025, following a Share Purchase Agreement signed on February 21, 2025. Additionally, the company acquired a 100% equity stake in Granules Pharmaceuticals GmbH (formerly Optus 1039 GmbH), Germany for EUR 28,400 on November 20, 2025. A new subsidiary, Granules Pharmaceuticals Canada, Inc., was incorporated on November 26, 2025.

The Board recommended a final dividend of ₹1.75 per equity share of ₹1 each. Furthermore, the company issued 25,000,000 warrants on a preferential basis at ₹585 per warrant, receiving ₹3,656.25 million as 25% of the total consideration on February 23, 2026.

Balance Sheet Strength

The consolidated balance sheet as of March 31, 2026, showed total assets of ₹77,199.50 million compared to ₹62,525.61 million in the previous year. Total equity increased to ₹50,849.95 million from ₹37,155.78 million, while total liabilities stood at ₹26,349.55 million. Cash and cash equivalents improved significantly to ₹8,802.38 million from ₹4,661.14 million at the end of FY25.

Granules India Limited has made the audio recording of its Q4 FY26 earnings conference call available online following the successful completion of the scheduled session on April 29, 2026. The pharmaceutical company filed the update on April 29, 2026, under Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Conference Call Completion and Recording Availability

The earnings conference call was conducted as scheduled on Wednesday, April 29, 2026, at 5:00 PM IST, where the company discussed its Q4 FY26 performance and overall business developments for the financial year ended March 31, 2026. The audio recording has been uploaded to the company's official website for stakeholder access.

Management Participation

The conference call featured senior management personnel who addressed queries and provided detailed insights into the company's performance. The participating executives represented key functional areas of the organization.

Regulatory Compliance and Documentation

The notification was filed pursuant to Regulation 46 of SEBI regulations, which mandates companies to maintain and update their websites with relevant information for stakeholders. The intimation was signed by Chaitanya Tummala, Company Secretary & Compliance Officer, and digitally authenticated on April 29, 2026, at 20:03:37 +05'00'.

Granules India Limited is headquartered at 15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India. The company maintains its investor relations through dedicated resources and provides regular updates to stakeholders through multiple communication channels.